Chondroid lesions are a broad family of bone growths that originate from cartilage-producing cells, ranging from harmless lumps found by accident on an X-ray to aggressive cancers that require radical surgery. The 2020 World Health Organization classification sorts cartilaginous tumors into three tiers: benign, intermediate, and malignant, with atypical cartilaginous tumors occupying an in-between category that can be surprisingly tricky to pin down.1RadiologÃa (English Edition). Update of cartilaginous tumours according to the WHO classification 2020 Because the behavior of these lesions spans such a wide spectrum, the treatment can be anything from periodic imaging to limb-sparing surgery to proton-beam radiation, and sometimes the hardest part is simply figuring out where a given lesion falls on that spectrum.
Benign Chondroid Lesions
Most chondroid lesions that doctors encounter are benign. The most common of these is the osteochondroma, a bony projection capped with cartilage that grows on the outer surface of a bone. Roughly 85% of osteochondromas are solitary, while about 15% appear as part of hereditary multiple exostoses, a genetic condition passed down in an autosomal dominant pattern.2PubMed Central. Osteochondromas: An Updated Review of Epidemiology, Pathogenesis, Clinical Presentation, Radiological Features and Treatment Options Osteochondromas often cause no symptoms at all. When they do, it is usually because they press on a nearby nerve or blood vessel, or because they cause a fracture or deformity during growth.
Enchondromas are another common benign type. These grow inside the bone, typically in the small bones of the hands and feet or in the long bones of the limbs. Many people live their entire lives with an enchondroma and never know it exists. When multiple enchondromas develop throughout the skeleton, the condition is known as enchondromatosis, which includes Ollier disease and Maffucci syndrome, both of which carry a risk of malignant transformation later in life.3PubMed Central. Malignant Transformation in Ollier’s Disease: A Novel Stem for a Tibial Megaprosthesis
Two rarer benign types deserve mention. Chondroblastoma is a destructive but non-cancerous lesion that typically appears in the end (epiphysis) of a long bone, often near a joint. It tends to show up in adolescents and young adults whose growth plates have not yet closed. Chondromyxoid fibroma, by contrast, favors the metaphysis of long bones and is one of the least common benign bone tumors.4PubMed Central. A rare case of epiphyseal chondromyxoid fibroma of the proximal tibia On imaging, chondroblastoma appears as a well-defined destructive area with a thin bright border, while chondromyxoid fibroma tends to be a larger, bubbly-looking lesion with a sharp sclerotic edge.5PubMed. Chondroblastoma and chondromyxoid fibroma
The Intermediate Category and Atypical Cartilaginous Tumors
One of the more confusing areas in orthopedic oncology is the space between clearly benign enchondromas and clearly malignant chondrosarcomas. The WHO’s intermediate category houses “atypical cartilaginous tumors” (ACTs), which used to be called grade 1 chondrosarcomas.1RadiologÃa (English Edition). Update of cartilaginous tumours according to the WHO classification 2020 The reclassification was not just a naming exercise. By moving these lesions out of the “cancer” column, the WHO acknowledged that ACTs in the limbs almost never metastasize and can often be managed with less aggressive surgery than a true malignancy would require.
That said, ACTs can still cause local bone destruction and, in rare cases, progress to a higher-grade chondrosarcoma. The challenge is that distinguishing an ACT from a benign enchondroma under the microscope can be genuinely difficult, even for experienced pathologists. One follow-up study of long-bone cartilage tumors found that clinical and radiological features sometimes failed to produce a statistically significant difference between the two diagnoses.6PubMed Central. Enchondroma versus Low-Grade Chondrosarcoma in Appendicular Skeleton: Clinical and Radiological Criteria Factors that tip the balance toward suspicion of a low-grade malignancy include pain on palpation, cortical involvement visible on CT or MRI, and increased uptake on a bone scan.7PubMed Central. Enchondroma versus Chondrosarcoma in Long Bones of Appendicular Skeleton: Clinical and Radiological Criteria—A Follow-Up
Chondrosarcoma and Its Subtypes
Chondrosarcoma is the malignant end of the chondroid spectrum and the second most common primary bone cancer after osteosarcoma. The current classification recognizes eight subtypes, including central conventional (graded 1 through 3), secondary peripheral, periosteal, dedifferentiated, mesenchymal, and clear cell chondrosarcoma.8PubMed Central. Classification of Chondrosarcoma: From Characteristic to Challenging Imaging Findings The conventional type is by far the most common. The rarer subtypes, including mesenchymal, clear cell, and dedifferentiated chondrosarcoma, together account for roughly 10% to 15% of all chondrosarcomas and carry a worse prognosis.9The American Journal of Pathology. Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGFβ as Potential Targets
Grade matters enormously. Low-grade conventional chondrosarcomas grow slowly and rarely spread beyond the bone. High-grade tumors behave aggressively, can metastasize to the lungs, and have a substantially worse survival rate. Dedifferentiated chondrosarcoma is particularly dangerous because part of the tumor transforms into a high-grade non-cartilaginous sarcoma, making it far more lethal than a conventional chondrosarcoma of any grade.
Symptoms and How Chondroid Lesions Are Found
Many chondroid lesions produce no symptoms at all. A study tracking low-grade chondroid tumors in the proximal humerus (upper arm bone) found that about 79% were discovered incidentally, meaning the patient was being evaluated for something else entirely, like a rotator cuff problem, when the lesion showed up on imaging.10PubMed Central. Natural history of intraosseous low-grade chondroid lesions of the proximal humerus This is one reason incidental chondroid lesions create so much clinical anxiety: you find something on a scan, but it may have been quietly sitting there for years without causing trouble.
When symptoms do appear, the most common one is a dull, aching pain in the affected bone that may worsen at night or with activity. Osteochondromas can create a palpable lump near a joint. If a lesion encroaches on nearby structures, you might experience numbness or tingling from nerve compression, swelling, or reduced range of motion. Higher-grade malignancies tend to produce more aggressive pain, and a pathologic fracture through a weakened area of bone can be the first sign that something is wrong. Pain that wakes you at night, new swelling over a bone, or a fracture from a minor injury are all red flags that warrant prompt imaging.
Imaging and the Diagnostic Puzzle
The first step in evaluating a suspected chondroid lesion is usually a plain X-ray, followed by CT or MRI. Cartilage tumors produce a characteristic pattern of calcification often described as “rings and arcs” or a “popcorn” appearance. These patterns represent calcified cartilage nodules surrounded by non-calcified cartilage, and they are a strong clue that a lesion is chondroid in origin.11PubMed Central. “Ring and arc” calcification in a rib mass MRI adds information about the extent of the tumor within the bone marrow and whether the cortex (the hard outer shell of the bone) has been breached, both of which help gauge aggressiveness.
Even with modern imaging, telling an enchondroma from a low-grade chondrosarcoma can be genuinely hard. The two can look nearly identical on scans, especially in the long bones. Genomic profiling is emerging as a supplementary tool. One study found that enchondromas and grade 1 chondrosarcomas have distinct molecular profiles: enchondromas more frequently carried IDH1 or IDH2 mutations (about 70% of cases) and had few copy-number changes, while chondrosarcomas more often showed numerous gains and losses across the genome and carried additional mutations in cancer genes like CDKN2A.12The American Journal of Surgical Pathology. Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma Sequencing is not yet routine for every cartilage lesion, but for borderline cases where biopsy is ambiguous, it may tip the diagnosis.
The Genetics Behind Chondroid Tumors
Two distinct genetic pathways account for most chondroid lesions. Enchondromas and their malignant cousins, conventional chondrosarcomas, are driven largely by mutations in the IDH1 and IDH2 genes, which encode metabolic enzymes. These mutations are found in the vast majority of enchondromas and have been identified in roughly 50% to 80% of chondrosarcomas.13PubMed Central. Enchondromatosis and Growth Plate Development In Ollier disease and Maffucci syndrome, somatic mosaic IDH mutations were found in about 87% of enchondromas and 70% of spindle cell hemangiomas, and roughly four in five affected individuals carried IDH1 or IDH2 mutations in their tumors.14Nature Genetics. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome Mouse studies have confirmed that mutant IDH is sufficient to initiate enchondroma formation, essentially by causing growth-plate cartilage cells to persist in the bone instead of being replaced during normal development.15PubMed Central. Mutant IDH is sufficient to initiate enchondromatosis in mice
Osteochondromas follow a different genetic route. They are linked to mutations in the EXT1 and EXT2 genes, which function as tumor suppressors. When these genes are knocked out, the result is abnormal cartilage-capped bony outgrowths. Most mutations in EXT1 and EXT2 cause premature truncation of the protein, consistent with a loss-of-function mechanism.16PubMed Central. Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses In families with hereditary multiple exostoses, mutations in one of these two genes account for the majority of cases.17PubMed. Comparison of fluorescent single-strand conformation polymorphism analysis and denaturing high-performance liquid chromatography for detection of EXT1 and EXT2 mutations in hereditary multiple exostoses
Surgical Treatment for Benign and Low-Grade Lesions
Most asymptomatic benign chondroid lesions do not need surgery. A solitary enchondroma found incidentally on imaging can be watched with periodic scans to make sure it is not growing or changing. Osteochondromas that are painless and not interfering with nearby structures are similarly managed with observation.
When surgery is needed for benign lesions or atypical cartilaginous tumors, the standard approach is curettage: the surgeon scrapes out the tumor from within the bone, often using cryosurgery (liquid nitrogen) to kill any remaining tumor cells, and then fills the cavity with bone graft or cement. This combination has a strong track record. One series of 46 patients treated with curettage and cryosurgery for low-grade cartilage tumors reported a recurrence rate of just over 4%, and functional scores averaged about 27 out of 30 on a standard musculoskeletal scale.18PubMed Central. Curettage and cryosurgery for low-grade cartilage tumors is associated with low recurrence and high function A larger series confirmed that curettage and cryosurgery for enchondromas and atypical cartilaginous tumors produces very good oncological results with a low recurrence rate.19PubMed Central. Curettage and cryosurgery for enchondroma and atypical cartilaginous tumors of the long bones: Oncological results of a large series
Long-term data reinforce these results. In a study following patients with low-grade chondrosarcoma treated by extended curettage and liquid nitrogen for a mean of about nine years, the local recurrence rate was under 3%, with no distant metastases or disease-related deaths, and functional outcomes remained excellent.20Orthopaedics & Traumatology: Surgery & Research. Long-term follow up of patients with low-grade chondrosarcoma in the appendicular skeleton treated by extended curettage and liquid nitrogen
Surgery for High-Grade Chondrosarcoma
High-grade chondrosarcomas (grades 2 and 3) demand a more aggressive surgical approach. The standard is wide surgical resection, meaning the tumor is removed en bloc with a cuff of normal tissue around it.21Journal of the American Academy of Orthopaedic Surgeons. Chondrosarcoma In the pelvis, spine, or shoulder girdle, achieving a truly wide margin can be technically difficult, and there is no consensus on exactly how wide “wide” needs to be.22PubMed Central. Is the Width of a Surgical Margin Associated with the Outcome of Disease in Patients with Peripheral Chondrosarcoma of the Pelvis? A Multicenter Study When margins are inadequate or the tumor recurs locally, outcomes worsen but are not necessarily hopeless. Even after a local recurrence, overall survival has been reported at about 74% at five years and 60% at ten years, though some patients experienced multiple recurrences requiring additional operations.23PubMed Central. Sixty Percent 10-year Survival of Patients With Chondrosarcoma After Local Recurrence
Depending on how much bone and soft tissue must be removed, reconstruction can involve metal implants, bone grafts, or combinations of both. For tumors involving the scapula (shoulder blade), for example, the extent of resection directly affects how well the shoulder functions afterward. Patients who undergo only a partial scapulectomy score significantly better on functional tests and retain more shoulder range of motion than those who need a total scapulectomy, whether reconstruction uses a prosthesis or a suspension technique.24PubMed Central. Oncologic and functional outcomes of different reconstruction modalities after resection of chondrosarcoma of the scapula: a medium- to long-term follow-up study The good news is that hand, wrist, and elbow function are generally preserved even in extensive shoulder procedures.
When Chemotherapy Does Not Work and Where IDH Inhibitors Fit
One of the frustrating realities of chondrosarcoma is that conventional chemotherapy and standard radiation are largely ineffective against it.25Current Molecular Biology Reports. Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? For patients whose tumors cannot be completely resected or who develop metastatic disease, treatment options have historically been very limited. This is what makes the IDH mutation story so interesting beyond its diagnostic value. Because a large proportion of chondrosarcomas carry IDH1 or IDH2 mutations, drugs that block these mutant enzymes are a natural therapeutic target. IDH inhibitors have already been approved for certain blood cancers, and early-phase trials in chondrosarcoma have shown modest activity.26PubMed Central. IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma “Modest” is a loaded word here: for a disease with almost no effective systemic treatment, even partial responses or disease stabilization represent a meaningful shift. Ongoing trials are looking at combining IDH inhibitors with other agents, but the final results are still pending.
Proton Therapy for Skull Base Lesions
Chondrosarcomas that arise at the base of the skull sit in one of the most surgically challenging locations in the body, nestled close to the brainstem, optic nerves, and major blood vessels. Complete surgical removal is often impossible, and standard photon radiation risks damaging those critical structures. Proton therapy offers a physical advantage here: protons deposit most of their energy at a specific depth (the Bragg peak) and then stop, which allows higher doses to be delivered to the tumor while sparing nearby tissue.27PubMed. Skull Base Chordoma and Chondrosarcoma: Neuroradiologist’s Guide to Diagnosis, Surgical Management, and Proton Beam Therapy
The published results are encouraging. One center reported that skull-base chondrosarcoma patients treated with pencil-beam scanning proton therapy achieved local control rates approaching 90% and overall survival above 93% at eight years.28Neuro-Oncology. Long-term outcomes and prognostic factors of skull-base chondrosarcoma patients treated with pencil-beam scanning proton therapy at the Paul Scherrer Institute Randomized data comparing proton and photon therapy head to head are still lacking, so the evidence rests on observational series, but the rationale and outcomes are strong enough that proton therapy has become a preferred option at many major centers for this particular indication.29PubMed Central. Proton Therapy for Skull Base Chondrosarcoma
Functional Recovery and Quality of Life After Surgery
The physical aftermath of chondrosarcoma surgery depends heavily on where the tumor was and how much tissue had to go. For lesions in the limbs treated with curettage alone, recovery is usually straightforward, and functional scores are high, as noted above. Spine and pelvis resections take a much heavier toll. In one series of patients who underwent mobile-spine chondrosarcoma resection, physical function and quality of life both fell significantly below population norms, and more than half experienced surgical complications within 90 days. Patients who needed reoperation fared worse on every patient-reported outcome measure.30PubMed Central. Physical Function and Quality of Life After Resection of Mobile Spine Chondrosarcoma These numbers are sobering, but they reflect the trade-off with a cancer that resists chemotherapy: surgery is often the only curative tool, and incomplete removal raises the risk of recurrence.
Chondroid Lesions in Children and Growth-Related Complications
Chondroid lesions near open growth plates in children and adolescents pose a special challenge. Chondroblastoma, for example, almost always sits in the epiphysis, right next to the joint surface and growth plate. Even successful curettage can damage the physis and lead to limb-length discrepancy. A long-term follow-up of 15 patients with epiphyseal chondroblastoma found upper-limb length differences of 2 to 10 cm when the tumor involved the proximal humerus, and lower-limb differences of 0.5 to 2 cm in patients with lower-extremity involvement.31PubMed. Epiphyseal chondroblastoma of bone. Long-term effects on skeletal growth and articular function in 15 cases treated surgically A more recent analysis of surgical outcomes for chondroblastoma found that about 7% of patients developed limb-length discrepancy ranging from 0.5 to 2 cm.32PubMed Central. Long term outcome of surgical treatment of chondroblastoma: analysis of local control and growth plate/articular cartilage related complications
Hereditary multiple exostoses, driven by EXT1 and EXT2 mutations, can also cause skeletal deformity during growth. The bony projections can alter limb alignment, restrict joint motion, and create forearm discrepancies when lesions near the wrist cause one bone to grow faster than its partner. Managing these children often requires a combination of orthopedic monitoring, serial imaging, and timed surgical interventions to correct alignment before skeletal maturity. The decision of when and whether to operate on a growing child’s exostosis balances the risk of the lesion itself against the risk that surgery near a growth plate will cause iatrogenic growth disturbance.